Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81
Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.
Share
Why It Matters
An expert analyst still likes AnaptysBio but thinks its stock might be worth less money. This means the company is still doing good work, but people should watch if the price keeps falling.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.